Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT02425605 Completed - Clinical trials for Hepatocellular Carcinoma

Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma

Start date: December 3, 2014
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, prospective phase 2 trial to assess the efficacy of localized concurrent chemoradiation therapy (CCRT) and sorafenib sequential therapy in subjects with advanced HCC. Approximately 47 subjects will be enrolled and will receive CCRT and sorafenib sequentially until all-cause mortality.

NCT ID: NCT02424955 Completed - Clinical trials for Hepatocellular Carcinoma

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

Start date: November 18, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.

NCT ID: NCT02423343 Completed - Solid Tumor Clinical Trials

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Start date: January 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC).

NCT ID: NCT02421185 Completed - Clinical trials for Carcinoma, Hepatocellular

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Start date: May 25, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine recommended Phase 2 dose [RP2D]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF) 19 amplification.

NCT ID: NCT02412579 Completed - Clinical trials for Hepatocellular Carcinoma

Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

Start date: March 2015
Phase:
Study type: Observational

The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.

NCT ID: NCT02409524 Completed - Clinical trials for Advanced Adult Hepatocellular Carcinoma

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

Start date: July 2016
Phase: Phase 2
Study type: Interventional

This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.

NCT ID: NCT02400788 Completed - Clinical trials for Hepatocellular Carcinoma

Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

Start date: April 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.

NCT ID: NCT02395523 Completed - Clinical trials for Hepatocellular Carcinoma

Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma

Start date: March 5, 2015
Phase: N/A
Study type: Interventional

This phase II study is to evaluate the effectiveness of hypofractionated proton beam therapy (PBT) for Hepatocellular Carcinoma patients in hepatitis B endemic area.

NCT ID: NCT02395250 Completed - Clinical trials for Hepatocellular Carcinoma

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Start date: March 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

NCT ID: NCT02387307 Completed - Melanoma Clinical Trials

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

rSIFN-01
Start date: July 2013
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).